MYASTHENIA GRAVIS

This study is testing whether a new medication called NMD670 can help reduce symptoms of myasthenia gravis, a condition that causes muscle weakness. About 84 adults with moderate to severe myasthenia gravis will take either the medication or a placebo pill twice daily for 21 days…

This study is testing a new drug called IM-101 to see if it is safe and if it can help control symptoms in adults with myasthenia gravis, a disease that causes severe muscle weakness. The trial will involve about 96 participants and will compare the effects of the drug to a place…

This study is reviewing past medical records to understand how well the drug zilucoplan worked for 55 French patients with myasthenia gravis, a disease that causes severe muscle weakness. Researchers are looking at whether the treatment improved patients' daily function, muscle s…

This study is testing an experimental cell therapy called KYV-101 for adults with generalized myasthenia gravis, a disease that causes severe muscle weakness. The therapy, known as CAR T, is designed to reset the immune system by removing harmful B cells that attack the body. Res…

This early-stage study is testing a new type of treatment called CD19-BCMA CAR-T therapy for adults with severe, treatment-resistant myasthenia gravis (MG). The main goals are to see if the treatment is safe and to find the best dose. Researchers will track side effects and check…

This study is testing whether adding a new drug called empasiprubart to an existing treatment (efgartigimod) can better control symptoms of myasthenia gravis. It will involve about 70 adults with a specific type of this muscle-weakening disease who have had only a partial improve…

This study aims to test the safety and effectiveness of several different drug combinations for people with myasthenia gravis, a condition that causes muscle weakness. It will enroll about 70 adults who have been diagnosed with the disease and are on stable treatment. The goal is…

This study is testing an investigational drug called nipocalimab to see if it can reduce symptoms and improve daily life for adults with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes severe muscle weakness. About 199 participants will be randomly a…

This study observes 30 adults in France with a severe, life-threatening flare-up of myasthenia gravis (a rare muscle-weakening disease) who are already in the intensive care unit (ICU). Doctors want to see if giving a newer drug called ravulizumab early, after standard emergency …

This study compares two experimental drugs, nipocalimab and efgartigimod, for adults with generalized myasthenia gravis—an autoimmune disease that causes severe muscle weakness. Researchers want to see which drug better reduces harmful antibodies and improves daily activities lik…

This is an early-stage safety study testing a new type of treatment called anito-cel for adults with generalized myasthenia gravis, a chronic autoimmune disease that causes severe muscle weakness. The therapy involves collecting a patient's own immune cells, genetically modifying…

This early-stage study is testing whether a modified immune cell therapy called CC-97540 is safe for people with multiple sclerosis or myasthenia gravis. The treatment uses specially engineered T-cells that target CD19, a protein on certain immune cells thought to drive these aut…

This study is testing an investigational drug called nipocalimab in children and teenagers with generalized myasthenia gravis (gMG), a rare disease that causes severe muscle weakness. The main goals are to see how the drug behaves in the body, if it is safe, and if it can help re…

This study is testing an existing drug, rozanolixizumab, in Chinese adults with generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness. The main goal is to see if the drug improves patients' ability to perform daily activities and reduces their muscle w…

This early-stage study is testing a new type of cell therapy for people with severe neurological autoimmune diseases that have not responded to other treatments. The therapy, called universal CAR T-cells, is designed to be given 'off-the-shelf' to target and reduce specific immun…

This study is testing whether light or moderate exercise is more suitable for people with myasthenia gravis, a condition that causes muscle weakness. Twenty adults will be randomly assigned to do either light or moderate group workouts three times a week for 12 weeks. Researchers…

This study is testing a special type of exercise for people with neuromuscular diseases (like ALS or muscular dystrophy) who often can't do regular workouts. It uses a suit that sends mild electrical signals to make muscles contract, aiming to improve strength, walking, balance, …

This study is testing whether two non-drug approaches—aerobic exercise or cognitive behavioral therapy—can help reduce severe fatigue in people with myasthenia gravis. Sixty adults with stable myasthenia gravis and significant fatigue will be randomly assigned to one of these 16-…

This study aims to monitor the long-term safety of the approved drug efgartigimod in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It will enroll about 680 patients, comparing those taking the drug to similar patients who are not. The m…

This study aims to create a large registry of people with Myasthenia Gravis (MG) to help researchers better understand the disease. It will enroll 800 adults with MG who are receiving care at Yale Neurology. The registry will collect health information, blood, and stool samples t…

This study aims to understand the safety of the medication efgartigimod during pregnancy and breastfeeding. It will follow women with conditions like myasthenia gravis who were exposed to the drug around conception, during pregnancy, or while nursing. Researchers will track pregn…

This study is testing whether smartphone recordings can help measure key symptoms of myasthenia gravis, a rare autoimmune disease that causes muscle weakness. Researchers will use video and audio from participants' phones to track symptoms like speech changes, eyelid drooping, an…